Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma W Hugo, JM Zaretsky, LU Sun, C Song, BH Moreno, S Hu-Lieskovan, ... Cell 165 (1), 35-44, 2016 | 3037 | 2016 |
Fulminant myocarditis with combination immune checkpoint blockade DB Johnson, JM Balko, ML Compton, S Chalkias, J Gorham, Y Xu, ... New England Journal of Medicine 375 (18), 1749-1755, 2016 | 2028 | 2016 |
Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis DY Wang, JE Salem, JV Cohen, S Chandra, C Menzer, F Ye, S Zhao, ... JAMA oncology 4 (12), 1721-1728, 2018 | 2023 | 2018 |
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ... The Lancet 395 (10241), 1907-1918, 2020 | 1850 | 2020 |
Completion dissection or observation for sentinel-node metastasis in melanoma MB Faries, JF Thompson, AJ Cochran, RH Andtbacka, N Mozzillo, ... New England Journal of Medicine 376 (23), 2211-2222, 2017 | 1400 | 2017 |
Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy H Shi, W Hugo, X Kong, A Hong, RC Koya, G Moriceau, T Chodon, R Guo, ... Cancer discovery 4 (1), 80-93, 2014 | 1057 | 2014 |
Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data F Finotello, C Mayer, C Plattner, G Laschober, D Rieder, H Hackl, ... Genome medicine 11, 1-20, 2019 | 940 | 2019 |
Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study JE Salem, A Manouchehri, M Moey, B Lebrun-Vignes, L Bastarache, ... The Lancet Oncology 19 (12), 1579-1589, 2018 | 883 | 2018 |
Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors S Das, DB Johnson Journal for immunotherapy of cancer 7 (1), 306, 2019 | 811 | 2019 |
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab AM Menzies, DB Johnson, S Ramanujam, VG Atkinson, ANM Wong, ... Annals of Oncology 28 (2), 368-376, 2017 | 809 | 2017 |
Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis JJ Moslehi, JE Salem, JA Sosman, B Lebrun-Vignes, DB Johnson The Lancet 391 (10124), 933, 2018 | 770 | 2018 |
Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immuno-Oncology … S Hendry, R Salgado, T Gevaert, PA Russell, T John, B Thapa, M Christie, ... Advances in anatomic pathology 24 (6), 311-335, 2017 | 693 | 2017 |
Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders DB Johnson, RJ Sullivan, PA Ott, MS Carlino, NI Khushalani, F Ye, ... JAMA oncology 2 (2), 234-240, 2016 | 628 | 2016 |
Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immunooncology … S Hendry, R Salgado, T Gevaert, PA Russell, T John, B Thapa, M Christie, ... Advances in anatomic pathology 24 (5), 235-251, 2017 | 623 | 2017 |
Non-genomic and immune evolution of melanoma acquiring MAPKi resistance W Hugo, H Shi, LU Sun, M Piva, C Song, X Kong, G Moriceau, A Hong, ... Cell 162 (6), 1271-1285, 2015 | 610 | 2015 |
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort … JL McQuade, CR Daniel, KR Hess, C Mak, DY Wang, RR Rai, JJ Park, ... The Lancet Oncology 19 (3), 310-322, 2018 | 546 | 2018 |
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy DB Johnson, MV Estrada, R Salgado, V Sanchez, DB Doxie, SR Opalenik, ... Nature communications 7 (1), 10582, 2016 | 528 | 2016 |
Comparison of biomarker modalities for predicting response to PD-1/PD-L1 checkpoint blockade: a systematic review and meta-analysis S Lu, JE Stein, DL Rimm, DW Wang, JM Bell, DB Johnson, JA Sosman, ... JAMA oncology 5 (8), 1195-1204, 2019 | 523 | 2019 |
Immune-checkpoint inhibitors: long-term implications of toxicity DB Johnson, CA Nebhan, JJ Moslehi, JM Balko Nature Reviews Clinical Oncology 19 (4), 254-267, 2022 | 509 | 2022 |
Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy D Shae, KW Becker, P Christov, DS Yun, AKR Lytton-Jean, S Sevimli, ... Nature nanotechnology 14 (3), 269-278, 2019 | 480 | 2019 |